---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004142"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:45:06.226415+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam provides 2024-2025 update: Phase 3 data, $835M cash, EMA filing in 2H25

## Summary
- BROADWAY Phase 3 met primary endpoint: 33% LS mean LDL-C reduction (p<0.0001); exploratory MACE reduction of 21%.
- Unaudited year-end cash of $835 million; funds operations through PREVAIL CVOT readout and potential commercial launch.
- Menarini to submit EMA filing for obicetrapib in 2H2025; additional Phase 3 data presentations planned throughout 2025.
- VINCENT Phase 2 trial exploring obicetrapib +/- PCSK9i on Lp(a) expected to complete in 2H2025.
- USPTO issued composition-of-matter patent for obicetrapib, providing IP protection in US until July 2043.

## SEC filing metadata
- accession: 0001193125-25-004142
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312525004142/0001193125-25-004142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312525004142/d837783d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004142
- JSON: https://secwatch.observer/filing/0001193125-25-004142.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004142.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.